Analysis and Commentary STEVEN GROSSMAN 4/26/24 Analysis and Commentary STEVEN GROSSMAN 4/26/24 Escaping the Downward Budget Pressures in FY 25 Read More Analysis and Commentary STEVEN GROSSMAN 4/19/24 Analysis and Commentary STEVEN GROSSMAN 4/19/24 The Alliance’s FY 25 Ask: Urgent Initiatives That Need More Funding Read More Analysis and Commentary STEVEN GROSSMAN 4/12/24 Analysis and Commentary STEVEN GROSSMAN 4/12/24 Alliance’s FY 25 Appropriations Request: Realistic for Meeting FDA’s Needs Read More Analysis and Commentary STEVEN GROSSMAN 4/5/24 Analysis and Commentary STEVEN GROSSMAN 4/5/24 President’s FY25 Budget Request: FDA Needs More Read More Analysis and Commentary STEVEN GROSSMAN 3/22/24 Analysis and Commentary STEVEN GROSSMAN 3/22/24 Preparing for the Alliance’s FY 25 “Ask” Read More Analysis and Commentary STEVEN GROSSMAN 3/15/24 Analysis and Commentary STEVEN GROSSMAN 3/15/24 Q&A About FDA Funding in FY 24 and FY 25 Read More Analysis and Commentary STEVEN GROSSMAN 3/8/24 Analysis and Commentary STEVEN GROSSMAN 3/8/24 Looking Ahead to the President’s FY25 Budget Request Read More Analysis and Commentary STEVEN GROSSMAN 3/1/24 Analysis and Commentary STEVEN GROSSMAN 3/1/24 Budget Angles: “Not All User Fees Are Alike” and “No Base, No Clarity” Read More Analysis and Commentary STEVEN GROSSMAN 2/23/24 Analysis and Commentary STEVEN GROSSMAN 2/23/24 5 Things to Know About the FY 24 Appropriations Endgame Read More Analysis and Commentary STEVEN GROSSMAN 2/16/24 Analysis and Commentary STEVEN GROSSMAN 2/16/24 Urging Members of Congress to Request Strong FDA Funding for FY 2025 Read More Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 4/26/24 Analysis and Commentary STEVEN GROSSMAN 4/26/24 Escaping the Downward Budget Pressures in FY 25 Read More
Analysis and Commentary STEVEN GROSSMAN 4/19/24 Analysis and Commentary STEVEN GROSSMAN 4/19/24 The Alliance’s FY 25 Ask: Urgent Initiatives That Need More Funding Read More
Analysis and Commentary STEVEN GROSSMAN 4/12/24 Analysis and Commentary STEVEN GROSSMAN 4/12/24 Alliance’s FY 25 Appropriations Request: Realistic for Meeting FDA’s Needs Read More
Analysis and Commentary STEVEN GROSSMAN 4/5/24 Analysis and Commentary STEVEN GROSSMAN 4/5/24 President’s FY25 Budget Request: FDA Needs More Read More
Analysis and Commentary STEVEN GROSSMAN 3/22/24 Analysis and Commentary STEVEN GROSSMAN 3/22/24 Preparing for the Alliance’s FY 25 “Ask” Read More
Analysis and Commentary STEVEN GROSSMAN 3/15/24 Analysis and Commentary STEVEN GROSSMAN 3/15/24 Q&A About FDA Funding in FY 24 and FY 25 Read More
Analysis and Commentary STEVEN GROSSMAN 3/8/24 Analysis and Commentary STEVEN GROSSMAN 3/8/24 Looking Ahead to the President’s FY25 Budget Request Read More
Analysis and Commentary STEVEN GROSSMAN 3/1/24 Analysis and Commentary STEVEN GROSSMAN 3/1/24 Budget Angles: “Not All User Fees Are Alike” and “No Base, No Clarity” Read More
Analysis and Commentary STEVEN GROSSMAN 2/23/24 Analysis and Commentary STEVEN GROSSMAN 2/23/24 5 Things to Know About the FY 24 Appropriations Endgame Read More
Analysis and Commentary STEVEN GROSSMAN 2/16/24 Analysis and Commentary STEVEN GROSSMAN 2/16/24 Urging Members of Congress to Request Strong FDA Funding for FY 2025 Read More
Analysis and Commentary STEVEN GROSSMAN 2/9/24 Analysis and Commentary STEVEN GROSSMAN 2/9/24 Developing the Alliance’s FY 2025 Recommendations Read More
Analysis and Commentary STEVEN GROSSMAN 2/2/24 Analysis and Commentary STEVEN GROSSMAN 2/2/24 FY 24 Funding Is Not Settled; Yet FY 25 Is Coming Soon Read More
Analysis and Commentary STEVEN GROSSMAN 1/26/24 Analysis and Commentary STEVEN GROSSMAN 1/26/24 Status of FY 24 and FY 25 Funding for FDA: Addressing Some FAQs Read More
Analysis and Commentary STEVEN GROSSMAN 1/12/24 Analysis and Commentary STEVEN GROSSMAN 1/12/24 What Happens to FDA If There is a Shutdown Read More
Analysis and Commentary STEVEN GROSSMAN 1/5/24 Analysis and Commentary STEVEN GROSSMAN 1/5/24 No Predetermined Outcome in Budget Negotiations Read More
Analysis and Commentary STEVEN GROSSMAN 12/15/23 Analysis and Commentary STEVEN GROSSMAN 12/15/23 Uncertainty, As Well As Risk to FDA in FY24 Appropriations Process Read More
Analysis and Commentary STEVEN GROSSMAN 12/8/23 Analysis and Commentary STEVEN GROSSMAN 12/8/23 FDA Funding At Risk In Current Budget Negotiations Read More
Analysis and Commentary STEVEN GROSSMAN 12/1/23 Analysis and Commentary STEVEN GROSSMAN 12/1/23 What Must End, Will End. But When and How? Read More
Analysis and Commentary STEVEN GROSSMAN 11/17/23 Analysis and Commentary STEVEN GROSSMAN 11/17/23 “Nothing Resolved. Everything Still on the Table.” Read More
Analysis and Commentary STEVEN GROSSMAN 11/15/23 Analysis and Commentary STEVEN GROSSMAN 11/15/23 Shutdown Threats: Second Verse Same as the First; FDA Budget Still at Risk Read More
